DR. DANA PHILLIP WOODS MD
Prescription History 1639140213
Ophthalmology in Willimantic, CT


Quality Rating: 75.44 out of 100 score

NPI Status: Active since January 31, 2006

Contact Information

83 QUARRY ST
WILLIMANTIC, CT
ZIP 06226
Phone: (860) 423-1619
Fax: (860) 423-7640

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DANA PHILLIP WOODS MD, an active Ophthalmology specialist practicing in Willimantic, CT. Our medical registry currently tracks 22 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,760 documented patient claims. Among these therapy options, the most frequently utilized medication is Timolol Maleate, which accounts for 545 claims alone.


Alphagan P

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 18
30-Day Fills 50.8
Days Supply 1,520
CT State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills66.5
Peer Average Days Supply1,915
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,415.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$523.09

State Avg Cost Per Claim

$438.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Betoptic S

Generic Formulation: Betaxolol HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 30.8
Days Supply 925
CT State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply909
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,043.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$503.63

State Avg Cost Per Claim

$412.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. Betaxolol belongs to a class of drugs known as beta blockers and works by decreasing the amount of fluid that is made within the eye.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 13
30-Day Fills 39.2
Days Supply 1,175
CT State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills103.7
Peer Average Days Supply3,031
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.0% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,215.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$93.53

State Avg Cost Per Claim

$74.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Brimonidine Tartrate-Timolol

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 36
30-Day Fills 72.4
Days Supply 2,129
CT State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills56.1
Peer Average Days Supply1,630
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,176.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$338.23

State Avg Cost Per Claim

$344.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Brinzolamide

Generic Formulation: BrinzolamideSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 27
30-Day Fills 64.4
Days Supply 1,918
CT State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills63.6
Peer Average Days Supply1,898
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,247.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$379.52

State Avg Cost Per Claim

$342.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Brinzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Combigan

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 45
30-Day Fills 91.1
Days Supply 2,677
CT State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills78.4
Peer Average Days Supply2,277
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,794.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$528.76

State Avg Cost Per Claim

$452.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Cyclosporine

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 31
30-Day Fills 75.0
Days Supply 2,250
CT State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills37.2
Peer Average Days Supply1,087
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 63.2% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $36,942.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,191.70

State Avg Cost Per Claim

$890.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 67
30-Day Fills 171.1
Days Supply 5,132
CT State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills196.0
Peer Average Days Supply5,869
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,632.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$54.21

State Avg Cost Per Claim

$40.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 372
30-Day Fills 803.2
Days Supply 23,735
CT State Average Benchmarks
Peer Average Claims125.0
Peer Average 30-Day Fills242.5
Peer Average Days Supply6,977
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 197.6% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,687.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.73

State Avg Cost Per Claim

$28.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 129
30-Day Fills 281.4
Days Supply 8,397
CT State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills129.1
Peer Average Days Supply3,772
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 101.6% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $91,872.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$712.19

State Avg Cost Per Claim

$553.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 524
CT State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills50.9
Peer Average Days Supply769
Conservative Utilization

This provider writes prescriptions for this formulation 34.7% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $312.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.77

State Avg Cost Per Claim

$15.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 32
30-Day Fills 50.3
Days Supply 1,364
CT State Average Benchmarks
Peer Average Claims128.0
Peer Average 30-Day Fills174.9
Peer Average Days Supply4,621
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,657.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.78

State Avg Cost Per Claim

$51.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Prednisone

Generic Formulation: PrednisoneSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 19
30-Day Fills 22.8
Days Supply 648
CT State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills60.6
Peer Average Days Supply1,246
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.6% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $223.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.77

State Avg Cost Per Claim

$7.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Restasis

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 168
30-Day Fills 356.0
Days Supply 10,650
CT State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills98.0
Peer Average Days Supply2,902
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 242.9% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $246,370.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,466.49

State Avg Cost Per Claim

$1,318.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Restasis Multidose

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 28.0
Days Supply 836
CT State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills19.4
Peer Average Days Supply560
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,485.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,623.81

State Avg Cost Per Claim

$869.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Rocklatan

Generic Formulation: Netarsudil Mesylat/LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 38
30-Day Fills 62.2
Days Supply 1,756
CT State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills70.7
Peer Average Days Supply1,998
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,437.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$564.15

State Avg Cost Per Claim

$594.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil/latanoprost is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). Lowering high pressure inside the eye can help prevent vision loss or blindness.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 14
30-Day Fills 26.9
Days Supply 808
CT State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills56.2
Peer Average Days Supply1,649
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,289.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$377.79

State Avg Cost Per Claim

$276.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 545
30-Day Fills 1,416.5
Days Supply 42,301
CT State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills155.6
Peer Average Days Supply4,614
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 701.5% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,624.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.33

State Avg Cost Per Claim

$40.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Travoprost

Generic Formulation: TravoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 37
30-Day Fills 106.0
Days Supply 3,179
CT State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills71.7
Peer Average Days Supply2,097
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,450.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$660.81

State Avg Cost Per Claim

$293.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 22.0
Days Supply 571
CT State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills31.9
Peer Average Days Supply731
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $901.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$75.16

State Avg Cost Per Claim

$58.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Vyzulta

Generic Formulation: Latanoprostene BunodSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 26
30-Day Fills 48.2
Days Supply 1,396
CT State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills59.3
Peer Average Days Supply1,704
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,009.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$577.29

State Avg Cost Per Claim

$504.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Latanoprostene bunod is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by controlling the flow of fluid within the eye to maintain a normal pressure.

Xiidra

Generic Formulation: LifitegrastSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 75
30-Day Fills 145.0
Days Supply 4,350
CT State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills54.8
Peer Average Days Supply1,647
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 141.9% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $105,925.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,412.34

State Avg Cost Per Claim

$1,168.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DANA PHILLIP WOODS MD provides transparency into local medical care patterns within Willimantic, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.